Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629289 | 1.00 | GRIK1 (0.55) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12762358 | 1.00 | GRIK1 (0.55) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12629396 | 1.00 | GRIK1 (0.55) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12762359 | 0.79 | SLC1A3 (0.67) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2266372 | 0.79 | SLC1A3 (0.67) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13636190 | 0.77 | SLC1A1 (0.64) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13957619 | 0.76 | GRB2 (0.54) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5300296 | 0.72 | GRB2 (0.52) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL25182268 | 0.71 | IDO1 (0.47) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22444783 | 0.71 | IDO1 (0.47) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20110104057-A1 | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110104057-A1 | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110104057-A1 | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | GLUL, GATD3, QPCT | GRIK1 26/4885GRIK2 33/4885SLC1A3 7/4885 |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | GLUL, GATD3, QPCT | GRIK1 28/4885GRIK2 32/4885SLC1A3 5/4885 |
| US-20110104057-A1 | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (II), their use and processes for their preparation | GLUL, QPCT, SLC1A2 | GRIK1 43/4885GRIK2 30/4885SLC1A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.